Company intelligence / Profile preview

Armatus Bio

Columbus, Ohio, United Statesarmatusbio.com ↗

Ownership: Private
Employees: ~8
Development stage: Preclinical

Overview

Lead candidate for CMT1A has received Orphan Drug Designation and Rare Pediatric Drug Designation, advancing toward IND-enabling studies as of Q2 2024. Also developing a preclinical vectorized RNAi asset for FSHD.[6]

Therapeutic areas: Neurology
Modalities: Vectorized RNAiAAV-based gene therapy
Industry: Biotech

Drug pipeline

4 assets

ARM-201

Preclinical

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Armatus Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Armatus Bio.

Explore the full profile